Top Biotech Companies in Sydney (26)
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love...
Smith & Nephew's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show mid-single-digit underlying growth through 2024–2025, with management reiterating guidance for continued growth in 2026. Early 2026 updates indicate broad-based contributions across units despite some subsegment variability.
Profitability: Trading profit and margins improved, supported by execution of the 12‑Point Plan and the transition to the RISE strategy. Management is guiding to further profit growth alongside higher returns.
Healthy Cash Flow: Free cash flow strengthened in 2025 with guidance for robust generation in 2026. Share repurchases completed and newly announced buybacks signal confidence and disciplined capital allocation.
Novotech is a global full‑service clinical research organization (CRO) and scientific advisory partner that provides clinical trial execution, regulatory, laboratory and consulting services to biotech and small- to mid‑sized pharmaceutical companies. Operating across the Asia‑Pacific region and beyond with multiple offices and strategic site partnerships, Novotech helps sponsors accelerate development and access diverse patient populations for global drug development.
Novotech is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, "Novotech" and "PPC". Novotech is a full-service clinical CRO with labs, phase I facilities, and drug development consulting services.
Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging...
Cepheid's Top Stability & Growth Strengths
Strong Market Position & Advantage: Evidence portrays Cepheid as a leader in near‑patient/sample‑to‑answer molecular diagnostics with a very large GeneXpert installed base and broad global reach. Multiple updates cite WHO‑endorsed TB assays and tens of thousands of instruments (exceeding 60,000 by 2024) underpinning recurring cartridge demand.
Innovation-Driven Growth: Recent regulatory wins (e.g., FDA clearance of the Xpert GI Panel and first‑in‑class POC HCV RNA authorization) and ongoing menu expansion signal sustained product innovation. Commentary highlights rapid test development and deployment across infectious diseases, helping drive non‑respiratory growth.
Strategic Partnerships: Collaborations with Oxford Nanopore, the Fleming Initiative, Oxford University, and CDC designations for rapid diagnostic advancement indicate strong ecosystem ties. These alliances aim to broaden use cases and strengthen platform adoption across settings.
Defining and optimising TBI diagnosis and prognosis to maximise patient outcomes.To increase the understanding of brain related injury with particular emphasis on concussion (mTBI) through ongoing research and education, and to ultimately validate a biomarker(s) that will be used in combination with dedicated point of care (POC) device as a definitive diagnostic/prognostic tool. A group of dedicated professionals working in collaboration...
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and...
Elekta's Top Stability & Growth Strengths
Strong Market Position & Advantage: Elekta is a top-tier radiotherapy vendor with category leadership in cranial stereotactic radiosurgery and a notable presence in high-field MR-guided therapy, reinforcing durable competitive standing. Recognition for oncology information systems further supports its positioning in cancer centers.
Innovation-Driven Growth: Recent launches such as Elekta Evo and the Elekta ONE software suite, alongside continued advancement of Unity MR‑Linac workflows, indicate a pipeline that is aiding orders and improving mix. These innovations underpin adaptive and image‑guided therapy strategies across the portfolio.
Resilient & Sustainable Growth: Book‑to‑bill ratios above 1.0 and low single‑digit constant‑currency sales growth point to steady underlying expansion. Improving adjusted margins in recent quarters suggest operational gains despite macro headwinds.
Building with biology. Hydrogen and Renewable Energy, On-site and On-Demand
Psylo is a drug development company focused on next generation psychedelics; our goal is to make broadly accessible medicines as improved treatments to currently available SSRI medications, using psychedelic molecules as the starting point. We are building a pipeline of novel molecules with the ultimate goal of taking leading candidates through to clinical trials.
Ingram Micro helps businesses Realize the Promise of Technology™. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and...
Ingram Micro's Top Stability & Growth Strengths
Strong Revenue Growth: Company updates show net sales grew in FY2025 and continued to rise year over year into early 2026, with multiple consecutive growth quarters during 2025. Feedback suggests momentum was broad‑based across regions and core lines such as Cloud, notebooks/endpoint, and Advanced Solutions.
Strong Market Position & Advantage: Industry coverage consistently places the company among the top two global IT distributors by revenue, reinforced by deep vendor relationships and extensive geographic reach. Feedback suggests this leadership position supports ecosystem influence and partner access across hardware, software, and cloud.
Innovation-Driven Growth: Management highlights the Xvantage digital platform and cloud marketplace as drivers improving partner experience and sell‑through. Evidence in the updates links platform investment to gains in Cloud and services and to the return to year‑over‑year growth exiting 2024 and through 2025.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
ICON plc's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.
Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.
Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring,...
Levur produces natural-identical oils, without the environmental impact. Our vision is a future where reliance on unsustainable plant and animal oils like Palm Oil or Tallow is drastically reduced, mitigating environmental impacts. From our base in Australia, we are collaborating with large consumer goods manufacturers to make this a reality at scale and ensure ethical alternatives are available to consumers...
Caprion Biosciences was a leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry, specializing in advanced immunology and proteomics services. It has since rebranded to CellCarta, a global contract research organization.
2San is a global diagnostics company that provides innovative home-testing and diagnostic solutions to empower individuals to take control of their health. Focusing on areas such as infection, drugs of abuse, and family planning, the company aims to make high-quality healthcare accessible and affordable for everyone through its goal of 'self-testing for all.'
At Eucalyptus, we run a trusted group of digital healthcare clinics on our telehealth platform including Pilot (men’s health), Kin (fertility), Software (dermatology) and Juniper (weight loss and menopause). Our mission is to bring high-touch, high-quality healthcare to patients around the world by empowering practitioners with technology. Since 2019, we’ve facilitated over one million consultations across Australia, the UK and...
We exist to help make medical research breakthroughs happen by expediting and enabling a better clinical trial process - for everybody. Our suite of purpose-built and owned Evrima products and services are born of the clinical trial sector and are inherently solutions-focused. We efficiently and accurately connect a diverse range of trial participants, researchers and clinicians, delivering an optimum clinical...
Caidya is a multi-therapeutic clinical research organization (CRO) serving innovators worldwide. Focused on delivery excellence and an elevated customer experience, Caidya offers a wide range of clinical services and vast therapeutic expertise, supporting its partners from pre-IND strategy, through clinical development to submission and post-marketing surveillance. Caidya leverages industry-leading and proprietary clinical technology to ensure trial transparency and data-driven decision-making. Formed...
KCR is a clinical development solutions provider creating value for emerging biotechnology organizations. Founded in 1997, our expert teams support clients with full-service clinical development capabilities. As part of the ICON organization, KCR serves clients globally with key operations hubs in Boston, US, Berlin, Germany, and Warsaw, Poland. KCR’s bespoke approach to service delivery for emerging Biotech companies combined with the...
ADInstruments is committed to providing innovative tools for research and education. Our company helps scientists and educators achieve their goals with our industry leading PowerLab and LabChart data acquisition systems. Since 1988, life science research has been and continues to be a key driver for innovation in our research product line. Today there are 40,000 ADInstruments data acquisition systems used...































